Compugen Ltd. (NASDAQ:CGEN) Shares Bought by Squarepoint Ops LLC

Squarepoint Ops LLC grew its position in Compugen Ltd. (NASDAQ:CGEN) by 23.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 85,693 shares of the biotechnology company’s stock after acquiring an additional 16,253 shares during the quarter. Squarepoint Ops LLC owned about 0.10% of Compugen worth $144,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Heron Bay Capital Management purchased a new position in Compugen during the 1st quarter worth $32,000. Secure Asset Management LLC purchased a new position in shares of Compugen during the second quarter worth about $69,000. Rothschild Investment LLC purchased a new position in shares of Compugen during the second quarter worth about $380,000. Finally, ARK Investment Management LLC grew its holdings in shares of Compugen by 4.7% during the second quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock worth $1,850,000 after buying an additional 48,979 shares during the last quarter. 12.22% of the stock is currently owned by hedge funds and other institutional investors.

Compugen Stock Performance

CGEN stock opened at $1.72 on Monday. The firm has a 50 day moving average of $1.85 and a 200-day moving average of $1.95. Compugen Ltd. has a 12-month low of $0.53 and a 12-month high of $3.03. The company has a market cap of $153.49 million, a price-to-earnings ratio of -17.20 and a beta of 2.64.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.06. The company had revenue of $6.70 million for the quarter, compared to analyst estimates of $2.68 million. During the same quarter in the previous year, the business posted ($0.11) earnings per share. Sell-side analysts forecast that Compugen Ltd. will post 0.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Compugen from a “hold” rating to a “buy” rating in a report on Thursday, August 15th.

Compugen Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.